Harbor Advisors’s AstraZeneca AZN Stock Holding History

Harbor Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6,000	Closed	-$421K	–	179
2018 Q2	$421K	Hold	6,000	–	–	0.14%	106
2018 Q1	$420K	Hold	6,000	–	–	0.14%	102
2017 Q4	$416K	Hold	6,000	–	–	0.14%	100
2017 Q3	$407K	Hold	6,000	–	–	0.15%	90
2017 Q2	$409K	Hold	6,000	–	–	0.16%	85
2017 Q1	$374K	Hold	6,000	–	–	0.16%	84
2016 Q4	$328K	Buy	+6,000	New	+$341K	0.16%	86

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Harbor Advisors's AZN Position: Q3 2018 in Review

Harbor Advisors sold out of AstraZeneca (AZN) in Q3 2018, closing a stake of 6,000 shares — an estimated $421K sold.

Harbor Advisors first reported a position in AZN in Q4 2016 and held it in 7 quarters. The position peaked at $421K in Q2 2018. 544 funds tracked by Wall St. Rank hold AZN as of Q3 2018.

Harbor Advisors reported no remaining AstraZeneca position as of Q3 2018 after selling out during the quarter.
Harbor Advisors sold 6,000 AstraZeneca shares in Q3 2018, an estimated $421K.
Harbor Advisors first reported a position in AstraZeneca in Q4 2016 and held it in 7 quarters.
Harbor Advisors's AstraZeneca position peaked at $421K in Q2 2018.
544 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2018.

Based on Harbor Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.